Where Consensus Went Off Track
We returned to primary data on Alzheimer’s and Parkinson’s rather than recycled reviews. Across pivotal experiments the field repeatedly confused correlation with causation, promoted surrogate biomarkers as causal drivers, and multiplied confusion. Correcting these errors reveals a more complete model that aligns with core science and explains bedside anomalies physicians have flagged for years.

Grassroots Clinician Network
We equip frontline clinicians with the new biology, generating real‑time response curves long before public trials. Each doctor becomes a data node, feeding outcomes back into the thesis and accelerating refinement.

Capital as an Accelerator
Fresh funding will:

• Double the pace of clinician onboarding

• Launch additional clinician‑led trials and support the grass root peer‑reviewed movement and publications

• Convert our training programme into an on‑demand digital platform for rapid scale

• Subsidise biomarker testing

• Expand the field‑coordinator team to support a larger clinician roster
  Each additional clinician broadens our privileged dataset and forces consensus to adjust more quickly.

Publication Pipeline
New peer‑reviewed publications will validate the mechanism, amplify grassroots momentum, and intensify pressure on mispriced assets we have already mapped. Because the research agenda runs through our own network, we can accelerate the timeline and align each paper with strategic market positioning.

Market Implications
Drug pipelines, consensus models, and treatment guidelines rest on an outdated map of disease biology, with over $300 billion in market capitalization tied to assumptions our data now challenges. Once that map is redrawn, selected valuations cannot stand. Our thesis is evidence based. It pinpoints scientific dislocations in neurodegenerative diseases  and shows how to convert them into disciplined portfolio positions.  The price still reflects the old map. Market will reward the ones that understand it ahead of consensus.